Molecular Diagnosis of Low-Grade Brain Tumors
This event has passed and can no longer be viewed
This event was presented live or live-streamed and has not been designated for on-demand presentation.
Case 1. A patient with pilocytic astrocytoma that has FGFR1 and PIKC3A mutations. Case 2. A patient with a glioneuronal tumor that has MYCN amplification and methylation profiling. This Texas Children's Cancer Center Genomics Tumor Board Series session will take place on Wednesday, September 14, 2022 at 12:00 P.M. Attendance will only be available virtually through Zoom.
Activity Information
Needs Statement
Pediatric oncologists, geneticists, molecular and anatomic pathologists, surgeons, advanced practice providers, genetic counselors, medical trainees, and other healthcare professionals require regular updates on recent advances in the field of pediatric oncology. A multidisciplinary case approach will be used to interpret clinically significant tumor and germline molecular findings (therapeutic, prognostic, and diagnostic) identified through advanced sequencing platforms. The tumor board aims to expand the knowledge of learners, evaluate advances in pediatric oncology research, implement evidence-based guidelines in clinical practice, enhance the quality of pediatric oncology care, and improve patient outcomes.
Educational Objectives
At the conclusion of the sessions, the participants should be able to:
- Apply the results of tumor and germline molecular testing to the diagnosis, prognosis, and treatment of pediatric cancer.
- Demonstrate the expanding role of molecular diagnostics in formulating pediatric precision-oncology treatment strategies.
- Use a multidisciplinary approach to interpret results of molecular diagnostics.
- Appraise the molecular tests currently available in pediatric oncology and recognize the limitations and risks of using them.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Residents
- Other Health Professionals
Specialties
- Medical Genetics and Genomics
- Pathology
- Pediatrics
Interest Groups
- Hospital Medicine
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Director
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenters
-
Frank Lin, M.D., Ph.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Sarah Scollon, M.S., C.G.C.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Qing Wei, M.D., Ph.D.
Molecular Genetic Pathology Fellow
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Activity Director
-
Frank Lin, M.D., Ph.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Planning Committee Members
-
Kevin Fisher, M.D., Ph.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Frank Lin, M.D., Ph.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Donald Williams Parsons, M.D., Ph.D.
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
-
Angshumoy Roy, M.D., Ph.D.
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Sarah Scollon, M.S., C.G.C.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Health Topics
Presenters: